Haemonetics
301 hedge funds and large institutions have $4.19B invested in Haemonetics in 2023 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 113 increasing their positions, 112 reducing their positions, and 35 closing their positions.
61% more call options, than puts
Call options by funds: $8.61M | Put options by funds: $5.34M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
26% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 35
7% more capital invested
Capital invested by funds: $3.9B → $4.19B (+$282M)
2% more funds holding
Funds holding: 294 → 301 (+7)
1.08% more ownership
Funds ownership: 99.53% → 100.61% (+1.1%)
1% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 112
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$56.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$51.1M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$30.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$20.5M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$36.9M |
| 2 |
Millennium Management
New York
|
-$33.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27.9M |
| 4 |
Neuberger Berman Group
New York
|
-$17.1M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$16.8M |
HAE Hedge Fund Activity: Q1 2023 in Review
301 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2023, worth a combined $4.19B — up 7.2% from $3.9B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new HAE positions and 35 closed out — a net gain of 9 holders — while 113 added to existing stakes and 112 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $56.5M. The largest seller was Wellington Management Group, cutting an estimated $36.9M.
- 301 institutional investors held Haemonetics (HAE) as of Q1 2023, up from 294 in Q4 2022.
- Funds reported $4.19B of Haemonetics stock for Q1 2023, up 7.2% quarter-over-quarter.
- 44 funds opened new Haemonetics positions in Q1 2023 and 35 closed out, a net change of +9 holders.
- The largest Haemonetics buyer in Q1 2023 was Capital Research Global Investors, an estimated $56.5M added.
- The largest Haemonetics seller in Q1 2023 was Wellington Management Group, an estimated $36.9M sold.
Based on aggregated 13F filings for Q1 2023.